Rhodes Jennifer J 4

What Happened
Jennifer J. Rhodes, EVP and Chief Legal Officer of ACADIA Pharmaceuticals, had 12,944 restricted stock units vest and convert to common shares on Feb 6, 2026. To cover tax withholding related to that vesting, 6,950 shares were sold in an open-market sale on Feb 9, 2026 at a weighted average price of $23.38, producing proceeds of $162,491. The remaining 5,994 shares from the vesting were retained.

Key Details

• Transaction dates: 2026-02-06 (RSU vesting/derivative conversion), 2026-02-09 (open-market sale). Form 4 filed 2026-02-10 (timely).
• Sale: 6,950 shares sold; weighted average price $23.38 (range $23.38–$23.40); proceeds $162,491. (F4)
• Vesting/conversion: 12,944 RSUs converted to shares on 2026-02-06 (reported as derivative exercise/conversion, code M). (F1, F5)
• Net retained from this vesting: 5,994 shares (12,944 vested − 6,950 sold).
• Other holdings: Includes 595 shares acquired via employee stock purchase plan on May 15, 2025. (F2)
• Reason for sale: Mandatory sale to cover withholding taxes and related items tied to RSU vesting; intended to comply with Rule 10b5-1(c) requirements. (F3)

Context
This was a routine, tax-withholding sale tied to RSU vesting (a cashless-style outcome) rather than a discretionary open-market sale signaling a view on the stock. For derivative events: RSUs vested and were converted into common shares, with a portion sold to satisfy withholding.